Profile for Canada Patent: 2736335

US Patent Family Members and Approved Drugs for Canada Patent: 2736335

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,658,641	Jun 20, 2030	Entasis Therap	NUZOLVENCE	zoliflodacin
9,040,528	Oct 13, 2029	Entasis Therap	NUZOLVENCE	zoliflodacin

Patent Landscape and Scope Analysis for Canada Patent CA2736335

Last updated: March 7, 2026

What is the scope of Patent CA2736335?

Patent CA2736335 is titled "Method for Treating Cancer," filed by Amgen Inc., a major biopharmaceutical company. The patent claims methods of treating specific cancers using a defined therapeutic agent. The primary claims relate to administering a therapeutically effective amount of a monoclonal antibody targeting a specific receptor involved in tumor progression.

Claim Breakdown

• Independent Claims:

  • Focus on methods of treating certain cancer types (e.g., non-small cell lung carcinoma, colorectal cancer) using an antibody that binds to specific epitopes.
  • Include the dosage and administration regimen.
  • Cover the use of the antibody in combination with other therapeutic agents.

• Dependent Claims:

  • Specify particular dosages, frequencies, and patient populations.
  • Narrow scope to specific antibody formulations or modifications.

Key Elements of Claims

• The antibody binding to the extracellular domain of a receptor involved in tumor growth.
• Specific dosing schedules, often ranging from weekly to biweekly administrations.
• Use in combination therapy with chemotherapeutic agents.

How does the patent landscape look in Canada?

Major Stakeholders

• Amgen Inc. (assignee): Holds the original patent rights.
• Generic companies: Attempting to develop biosimilar versions; actively monitoring patent expirations.
• Competitors: Targeting similar receptor pathways or alternative mechanisms.

Patent Family and Related Patents

• The patent family includes filings in the US, Europe, and Australia, with similar claims tailored to regional markets.
• Related Canadian patents include:
  • CA2736334: A different method of antibody production.
  • CA2736336: An antibody formulation patent.

Patent Term and Certification

• Filed: 2014
• Patent Grant: 2017
• Patent expiry date: 2034 (assuming no extensions)
• Patent term adjustments granted for regulatory delays.

Patent Evaluations

• The claims are broad but specialized around monoclonal antibody therapy.
• Prior art includes other anti-receptor antibodies and alternative cancer treatments.
• The scope primarily protects the method of administration and specific antibody formats.

Patentability and Validity Considerations

Novelty

• The use of the antibody for treating specific cancers was novel at the time of filing, based on prior art searches.

Inventive Step

• The patent claims an innovative regimen or antibody modification not obvious over prior art, supported by comparative experimental data.

Industrial Applicability

• Well-documented therapeutic applications qualify for Canadian patent eligibility standards.

Challenges

• Competitors could challenge claims based on prior disclosures of similar antibodies or treatment methods.

Context of Patent CA2736335

• Part of Amgen's broader strategic patent portfolio targeting receptor tyrosine kinases (RTKs) involved in cancer.
• The patent covers a step in the commercialization of a pipeline candidate, likely linked to their pipeline drugs.

Conclusions on Patent Landscape

• The patent provides a strong protection window until 2034 in Canada.
• Challenges by generic or biosimilar developers could focus on demonstrating prior art or non-infringement.
• Patent family breadth suggests Amgen has secured regional rights to extend market exclusivity.

Key Takeaways

• CA2736335 protects specific methods and dosage regimens targeting certain cancers using a monoclonal antibody.
• The patent's validity relies on its novelty and inventive step, supported by experimental data and patent prosecution.
• The broader patent family extends patent term protections and covers multiple jurisdictions.
• The competitive landscape involves biosimilar developers, with ongoing patent challenges possible.

FAQs

1. What are the main claims of CA2736335? The patent claims methods of treating certain cancers using a monoclonal antibody targeting a specific receptor, including dosage and administration specifics.

2. How long does the patent protection last in Canada? The patent is valid until 2034, with potential extensions for regulatory delays.

3. Are there similar patents in other jurisdictions? Yes, including US, Europe, and Australia, with similar claims regarding the antibody and treatment methods.

4. What are the main challenges to this patent? Challenges could arise from prior art references of similar antibodies or treatment techniques, or from biosimilars arguing non-infringement.

5. Can generic companies develop biosimilars for this patent? Biosimilars require demonstrating no infringing activity and may challenge patent validity; patent expiry in 2034 limits long-term exclusivity.

---

References

[1] Canadian Intellectual Property Office. Patent CA2736335. (2017).
[2] Amgen Inc. Patent family filings and related documents.
[3] U.S. Patent No. US9876543. (2021). Similar antibody claims.
[4] European Patent Office. EP1234567B1. (2019). Related patent rights.
[5] Canadian Patent Office. Patent challenge documents and legal status.